© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Co-Diagnostics, Inc. (CODX) stock declined over -2.26%, trading at $2.59 on NASDAQ, down from the previous close of $2.65. The stock opened at $3.49, fluctuating between $2.47 and $3.95 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 19, 2026 | 2.31 | 2.71 | 2.26 | 2.65 | 138.56K |
| Mar 18, 2026 | 2.22 | 2.33 | 2.18 | 2.31 | 74.46K |
| Mar 17, 2026 | 2.41 | 2.43 | 2.23 | 2.29 | 124.26K |
| Mar 16, 2026 | 2.57 | 2.65 | 0.00 | 0.00 | 183.23K |
| Mar 13, 2026 | 2.64 | 2.88 | 2.64 | 2.82 | 1.07M |
| Mar 12, 2026 | 3.16 | 3.16 | 2.70 | 2.70 | 122.9K |
| Mar 11, 2026 | 4.05 | 4.05 | 2.85 | 3.24 | 2.84M |
| Mar 10, 2026 | 2.20 | 4.40 | 2.20 | 4.31 | 259.86K |
| Mar 09, 2026 | 2.20 | 2.30 | 2.11 | 2.18 | 2.51K |
| Mar 06, 2026 | 2.05 | 2.33 | 2.05 | 2.23 | 2.11K |
| Mar 03, 2026 | 2.25 | 2.34 | 2.20 | 2.23 | 8.2K |
| Mar 02, 2026 | 2.25 | 2.30 | 2.25 | 2.30 | 1.7K |
| Feb 27, 2026 | 2.32 | 2.32 | 2.30 | 2.30 | 1.48K |
| Feb 26, 2026 | 2.21 | 2.49 | 2.15 | 2.30 | 5.46K |
| Feb 25, 2026 | 2.20 | 2.29 | 2.12 | 2.20 | 4.54K |
| Feb 24, 2026 | 2.20 | 2.39 | 2.20 | 2.33 | 1.77K |
| Feb 23, 2026 | 2.25 | 2.26 | 2.24 | 2.24 | 2.68K |
| Feb 20, 2026 | 2.44 | 2.45 | 2.21 | 2.25 | 14.5K |
| Feb 19, 2026 | 2.45 | 2.48 | 2.43 | 2.48 | 5.4K |
| Feb 18, 2026 | 2.48 | 2.56 | 2.40 | 2.52 | 10.11K |
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
| Employees | 132 |
| Beta | 1.4 |
| Sales or Revenue | $991.47K |
| 5Y Sales Change% | 71.611% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |